Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS

Recruiting

• Conditions: BK Virus Infection

• Registration Number: NCT05618275
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

The BK virus (BKV) belongs to the Polyomaviridae family. The primary infection, generally asymptomatic, occurs during childhood. The virus then persists in latent form in the body, mainly in the epithelial cells of the kidney and urinary tract. Cellular immunosuppression favors BKV replication. It is responsible for pathologies of the renal-urinary tract such as BKV-associated nephropathy (BKVAN) in kidney transplant recipients, hemorrhagic cystitis (HC) in hematopoietic stem cell (HSC) recipients or ureteral stenosis.

To date, there is no specific antiviral treatment against BKV. The management of patients is essentially symptomatic and requires a multidisciplinary approach. It is therefore necessary to identify early prognostic markers for the occurrence of CH and to develop new therapeutic strategies.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Status Verified: 2022-11
• Study First Submitted: 2022-11-08
• Study First Submitted QC: 2022-11-08
• Last Update Submitted: 2022-11-08
• Study First Posted: 2022-11-16
• Last Update Posted: 2022-11-16
• Primary Completion: 2022-12
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

• Opposition of the patient (or parental authority holders) to participate in the study
• Biological resources from a patient who does not meet all inclusion criteria
• Patient deprived of liberty or under court protection
• Patient under guardianship or curatorship

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective study of the role of anti-BKV neutralizing antibodies in HSCT patients in the pediatric oncology-hematology department of the HUS	Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined

Trial Locations

Locations (1)

Service Laboratoire de Virologie - PTM - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France